NCT05291598

Meloxicam for Pain Management After Total Joint Arthroplasty (TJA)

IV Meloxicam for Pain Management Post TJA: Prospective Randomized Trial

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 223 (actual)
• Sponsor: University of Miami · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this project is to determine if a change in patient reported pain, nausea and vomiting after total knee and hip arthroplasty could be observed with the substitution of Intravenous meloxicam for ketorolac in the current established peri-operative pain protocol and if these changes lead to a decrease in opioid consumption (in morphine equivalents).

Conditions

• Total Knee Replacement
• Total Hip Replacement

Interventions

Type	Name	Description
DRUG	IV meloxicam	Participants will be administered meloxicam 30 mg IV push pre-operatively.
DRUG	Ketorolac	Participants will be treated with ketorolac 15 mg IV push intra-operatively, followed by 15 mg IV push every 6 hours scheduled for 2 doses.

Timeline

• Start date: 2022-05-01
• Primary completion: 2023-05-01
• Completion: 2023-05-01
• First posted: 2022-03-22
• Last updated: 2024-08-14
• Results posted: 2024-08-14

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study